Ethiopia will receive 13 million praziquantel tablets in 2015

Merck (http://www.merckgroup.com), a leading company for innovative and top-quality, high-tech products in the pharmaceutical, chemical and life science sectors, today announced that Ethiopia will receive around 13 million praziquantel tablets in 2015. Merck supports the World Health Organization (WHO) to fight the parasitic worm disease schistosomiasis in Africa. Praziquantel is the most effective treatment for schistosomiasis. 

According to WHO, Ethiopia is one of the most endemic countries for schistosomiasis in the world. It is estimated that around 22 million people, which is more than 20% of the entire population, requires treatment. Since the start of the program around 1.4 million patients, primarily children, have been treated. “We have committed to continuing our efforts in Africa, in cooperation with WHO, until schistosomiasis is eliminated. In order to fulfill this commitment, we will donate 100 million praziquantel tablets to African countries in 2015. Ethiopia will be one of the main beneficiaries of this donation”, said Frank Gotthardt, Head of Public Affairs at Merck and responsible for the Merck Praziquantel Donation Program.

Yesterday, the first meeting of the Global Schistosomiasis Alliance took place at the UN Conference Centre in Addis Ababa. “This alliance will allow the different constituencies to engage in a coordinated approach to better address the challenges of meeting the elimination target”, commented Gotthardt. The round table discussions and first global schistosomiasis meeting took place during the neglected tropical diseases week being hosted by the Ethiopian government from December 8 to 12.

The Merck Praziquantel Donation Program was launched in 2007. Since then, more than 200 million tablets have been supplied and over 54 million children have been treated. Between 2011 and 2014, Merck’s annual donation has grown from 25 to about 75 million tablets. At the beginning of 2012, Merck announced that it will fight schistosomiasis until the disease has been eliminated in Africa. To reach this goal, the company will increase the annual donation of tablets up to 250 million in the medium term. The further scale-up of the program will allow the treatment of about 100 million children a year. The expanded Merck Praziquantel Donation Program will result in a financial commitment totaling around USD 23 million a year. In addition, Merck is also supporting awareness initiatives at African schools to explain the causes of schistosomiasis to children and teach them how to prevent the disease. Furthermore, Merck is conducting research on a pediatric formulation of praziquantel for preschool children within the scope of a public-private partnership. So far, praziquantel tablets can only be administered to children over the age of six.